Prevail Therapeutics is developing precision gene therapies utilizing AAV-based technology to slow or halt the progression of Parkinson's disease and other neurodegenerative disorders. By leveraging advancements in human genetics, the company aims to improve treatment outcomes for patients facing these debilitating conditions.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Parkinson's disease and other neurodegenerative disorders lack effective treatments that can halt or slow disease progression. Current therapies primarily address symptoms, failing to target the underlying genetic causes of these debilitating conditions.
Solution
Prevail Therapeutics is developing precision gene therapies designed to modify the course of Parkinson's disease and other neurodegenerative disorders. The company leverages adeno-associated virus (AAV)-based technology to deliver therapeutic genes directly to affected cells. This approach aims to address the genetic roots of these diseases, potentially slowing or stopping their progression and improving long-term outcomes for patients.
Target Audience
The primary target audience includes patients diagnosed with Parkinson's disease and other neurodegenerative disorders, as well as their families and caregivers.
Features
- AAV-based gene therapy platform for targeted delivery of therapeutic genes
- Focus on disease-modifying treatments rather than symptomatic relief
- Application of human genetics to identify and address underlying causes of neurodegenerative disorders